Intest Res.  2023 Jul;21(3):411-412. 10.5217/ir.2023.00030.

JAK inhibitor, a new player for treatment-refractory microscopic colitis

• Druez A
• Travis S
• Rahier JF

• KMID: 2544764
• DOI: http://doi.org/10.5217/ir.2023.00030

Reference

1. Tong J, Zheng Q, Zhang C, Lo R, Shen J, Ran Z. Incidence, prevalence, and temporal trends of microscopic colitis: a systematic review and meta-analysis. Am J Gastroenterol. 2015; 110:265–276.

2. Verhaegh BP, Münch A, Guagnozzi D, et al. Course of disease in patients with microscopic colitis: a European prospective incident cohort study. J Crohns Colitis. 2021; 15:1174–1183.

3. Weimers P, Vedel Ankersen D, Lophaven S, et al. Disease activity patterns, mortality, and colorectal cancer risk in microscopic colitis: a Danish nationwide cohort study, 2001 to 2016. J Crohns Colitis. 2021; 15:594–602.

4. Boivineau G, Zallot C, Zerbib F, et al. Biologic therapy for bude-sonide-refractory, -dependent or -intolerant microscopic colitis: a multicentre cohort study from the GETAID. J Crohns Colitis. 2022; 16:1816–1824.

5. Tagkalidis PP, Gibson PR, Bhathal PS. Microscopic colitis demonstrates a T helper cell type 1 mucosal cytokine profile. J Clin Pathol. 2007; 60:382–387.

6. Münch A, Langner C. Microscopic colitis: clinical and pathologic perspectives. Clin Gastroenterol Hepatol. 2015; 13:228–236.

7. De Vries LC, Wildenberg ME, De Jonge WJ, D’Haens GR. The future of Janus kinase inhibitors in inflammatory bowel disease. J Crohns Colitis. 2017; 11:885–893.

8. European Medicines Agency. EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders [Internet]. European Medicines Agency;2022. [cited 2023 Apr 24]. https://www.ema.europa.eu/en/news/ema-recommends-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic.